Every earnings call for ROSSARI — management tone, guidance, KPIs and promise tracking, quarter by quarter.
ROSSARI · 8 transcripts · Chemicals · latest Q1 FY27Rossari Biotech Limited has 8 earnings calls on record here, a Chemicals company, most recently Q1 FY27. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue from Operations ₹697 cr (+28% YoY); EBITDA ₹81 cr (+19% YoY); EBITDA Margin 11.6%. Revenue of ₹697.2 crores, up 28% YoY.
Read full transcript & analysisRevenue from Operations (Q4 FY26) ₹685 cr (+18% YoY); EBITDA (Q4 FY26) ₹77 cr (+11% YoY); EBITDA Margin (Q4 FY26) 11.3%. Q4 FY26 revenue from operations at ₹684.9 crore, up 18% YoY.
Read full transcript & analysisRevenue ₹582 cr (+13% YoY); EBITDA ₹69 cr; EBITDA Margin 11.8%. Consolidated revenues grew by 13% YoY to Rs. 581.7 crore.
Read full transcript & analysisRevenue ₹582 cr (+13% YoY); EBITDA ₹69 cr; EBITDA Margin 11.8%. Consolidated revenues grew 13% YoY to Rs. 581.7 crore in Q3 FY26.
Read full transcript & analysisRevenue ₹586 cr (+18% YoY); EBITDA ₹72 cr; EBITDA Margin 12.3%. Revenue for Q2 FY26 grew by 18% YoY to ₹586.1 crore.
Read full transcript & analysisRevenue from Operations ₹544 cr (+11% YoY); EBITDA ₹68 cr (+5% YoY); EBITDA Margin 12.5%. Revenue from operations grew 11.0% YoY to Rs. 543.7 crore in Q1 FY26.
Read full transcript & analysisRevenue ₹513 cr (+10% YoY); EBITDA ₹65 cr; EBITDA Margin 12.6%. Consolidated revenues increased by 10.5% YoY to ₹512.7 crore.
Read full transcript & analysisRevenue ₹498 cr (+3% YoY); EBITDA ₹66 cr (+4% YoY); EBITDA Margin 13.2%. Revenue increased by 3% YoY to ₹498.4 crores in Q2 FY25.
Read full transcript & analysis